Summary The International Initiative on Thrombosis and Cancer is an independent
academic working group of experts aimed at establishing global consensus for the treatment …

Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

Heparin has been used extensively as an antithrombotic and anticoagulant for close to 100
years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence …

Anticoagulants are the cornerstone for prevention and treatment of thrombosis but are not
completely effective, and concerns about the risk of bleeding continue to limit their uptake …

Background Bleeding risk is highly relevant for treatment decisions in cancer-associated
thrombosis (CAT). Several risk scores exist, but have never been validated in patients with …

Background Patients with cancer‐associated venous thromboembolism (VTE) are
recommended to receive treatment with therapeutic anticoagulation for at least 3–6 months …

Patients with cancer have an increased risk of venous-and arterial thromboembolism
(VTE/ATE). Anti-cancer treatments including surgery, radiotherapy, and certain …

The introduction of new therapeutic agents for multiple myeloma (MM), including
proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, has improved …

Cancer‐associated venous thromboembolism (VTE) is a leading cause of morbidity and
mortality in patients with cancer. Treatment of cancer‐associated VTE comes with a …

Cancer-associated thrombosis, with the incidence rising over the years, is associated with
significant morbidity and mortality in patients with cancer. Recent advances in the treatment …